NovoCure (NVCR) shares soared higher today as the company gave an update on a phase 3 trial of a treatment for non-small cell lung cancer.
More from Investing
The safe route is to buy shares, collect the generous dividends and reap the rewards when valuations revert back to normal.
These recently downgraded names are displaying both quantitative and technical deterioration.
LCID's market cap has been deflated, so is it now a bargain, or can it slip further?
The most powerful thing an investor can do is embrace the idea that they don't know what the future holds.